Search Results
488 results found for "Cost-efficient medications https://simplemedrx.top"
- Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results
ANAVEX®2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial in the second half of 2023 Company to host Webcast / Conference Call Information: Management will host a conference call on Tuesday May 9, 2023, (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most
- Anavex Life Sciences Announces 12-Month Data of ANAVEX 2-73 in a Alzheimer's Patients Study
Anavex is grateful for the dedication of the patients, their families and the clinical investigators Further information is available at http://www.ctad-alzheimer.com/. projected in any of such statements due to various factors, including the risks set forth in the Company’s most Investors: Matthew Haines River East Investor Relations, LLC (917) 733-9297 mhaines@rivereastir.com Media Dobson Media Group (203) 258-0159 dennisdobsonjr@dobsonmediagroup.com
- Anavex to Present at Ladenburg Thalmann 2016 Healthcare Conference
A live audio webcast of the presentation will be available on the conference website at http://wsw.com (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Investors: Matthew Haines River East Investor Relations, LLC (917) 733-9297 mhaines@rivereastir.com Media Dobson Media Group (203) 258-0159 dennisdobsonjr@dobsonmediagroup.com
- Anavex Life Sciences' Drug Shows Efficacy to Support Potential Disease Modification in Parkinson's
Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for mission of the WPC is to provide an international forum to disseminate the latest scientific discoveries, medical (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Dobson Media Group (203) 258-0159 dennisdobsonjr@dobsonmediagroup.com
- Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President of Regulatory Affairs
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most anavex.com Investors: Matthew Haines River East Investor Relations, LLC 917-733-9297 mhaines@rivereastir.com Media Dobson Media Group 203-258-0159 dennisdobsonjr@dobsonmediagroup.com Social Media: Bill Douglass Gotham
- Anavex Life Sciences to Present at Noble Capital Markets' Thirteenth Annual Investor Conference
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated anavex.com Investors: Matthew Haines River East Investor Relations, LLC 917-733-9297 mhaines@rivereastir.com Media Dobson Media Group 203-258-0159 dennisdobsonjr@dobsonmediagroup.com
- Anavex Life Sciences to Present at 14th Annual BIO Asia International Conference
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most anavex.com Investors: Matthew Haines River East Investor Relations, LLC 917-733-9297 mhaines@rivereastir.com Media Dobson Media Group 203-258-0159 dennisdobsonjr@dobsonmediagroup.com
- Anavex Life Sciences Obtains Permanent Dismissal of All Claims in Securities Lawsuit
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Investors: Matthew Haines River East Investor Relations, LLC 917-733-9297 mhaines@rivereastir.com Anavex Media Dobson Media Group (203) 258-0159 dennisdobsonjr@dobsonmediagroup.com
- Anavex Announces Positive Preclinical Results w/ ANAVEX 2-73 in Fragile X — Autism-Related Disorders
Fragile X syndrome is the most common form of inherited intellectual disability and the most frequent We would be very interested in continuing the work with ANAVEX 2-73,” said Michael Tranfaglia, MD, Medical About Fragile X Syndrome and Autism Spectrum Disorders Fragile X syndrome is the most common form of Autism Spectrum Disorder is a behavioral diagnosis while Fragile X syndrome is a medical/genetic diagnosis FRAXA Research Foundation is a non-profit, 501(c)3 organization which is dedicated to funding biomedical
- Anavex to Participate in Mizuho Therapeutics Conference
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most anavex.com Investors: Matthew Haines River East Investor Relations, LLC 917-733-9297 mhaines@rivereastir.com Media Dobson Media Group (203) 258-0159 dennisdobsonjr@dobsonmediagroup.com
- Anavex Life Sciences Novel Sigma-1 / Sigma-2 Ligand Shows Encouraging Results as an Analgesic
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most anavex.com Investors: Matthew Haines River East Investor Relations, LLC 917-733-9297 mhaines@rivereastir.com Media Dobson Media Group (203) 258-0159 dennisdobsonjr@dobsonmediagroup.com
- Anavex Compound to be Tested in Biogen Neurological Protection Model
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most anavex.com Investors: Matthew Haines River East Investor Relations, LLC 917-733-9297 mhaines@rivereastir.com Media Dobson Media Group (203) 258-0159 dennisdobsonjr@dobsonmediagroup.com
